Twin-to-twin transfusion syndrome: an antiangiogenic state?

American Journal of Obstetrics and Gynecology

Volumn 198, Issue 4, 2008, Pages 382.e1-382.e8

  Kusanovic, Juan Pedro ^a,b   Romero, Roberto ^a,b   Espinoza, Jimmy ^a,b   Nien, Jyh Kae ^c   Kim, Chong Jai ^a,b   Mittal, Pooja ^a,b   Edwin, Sam ^a   Erez, Offer ^a   Gotsch, Francesca ^a   Mazaki Tovi, Shali ^b   Than, Nandor G ^a   Soto, Eleazar ^b   Camacho, Natalia ^a,b   Gomez, Ricardo ^c   Quintero, Ruben ^d   Hassan, Sonia S ^a,b  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^d UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

angiogenesis; angiogenic factors; birthweight discordancy; endoglin; monochorionic; placental growth factor; PlGF; sFlt1; sVEGFR 1; TTTS; twin pregnancy

Indexed keywords

ENDOGLIN; PLACENTAL GROWTH FACTOR; VASCULOTROPIN RECEPTOR 1;

ADULT; ANTIANGIOGENIC ACTIVITY; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MATERNAL PLASMA; PRIORITY JOURNAL; TWIN PREGNANCY; TWIN TWIN TRANSFUSION SYNDROME;

EID: 41349106757     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2008.02.016     Document Type: Article

References (93)

1. Bajoria R., and Kingdom J. The case for routine determination of chorionicity and zygosity in multiple pregnancy. Prenat Diagn 17 (1997) 1207-1225
2. Dube J., Dodds L., and Armson B.A. Does chorionicity or zygosity predict adverse perinatal outcomes in twins?. Am J Obstet Gynecol 186 (2002) 579-583
3. Carroll S.G., Tyfield L., Reeve L., Porter H., Soothill P., and Kyle P.M. Is zygosity or chorionicity the main determinant of fetal outcome in twin pregnancies?. Am J Obstet Gynecol 193 (2005) 757-761
4. Sebire N.J., Snijders R.J., Hughes K., Sepulveda W., and Nicolaides K.H. The hidden mortality of monochorionic twin pregnancies. BJOG 104 (1997) 1203-1207
5. Gonzalez-Quintero V.H., Luke B., O'Sullivan M.J., et al. Antenatal factors associated with significant birth weight discordancy in twin gestations. Am J Obstet Gynecol 189 (2003) 813-817
6. Leduc L., Takser L., and Rinfret D. Persistance of adverse obstetric and neonatal outcomes in monochorionic twins after exclusion of disorders unique to monochorionic placentation. Am J Obstet Gynecol 193 (2005) 1670-1675
7. Sperling L., Kiil C., Larsen L.U., et al. Naturally conceived twins with monochorionic placentation have the highest risk of fetal loss. Ultrasound Obstet Gynecol 28 (2006) 644-652
8. Bejar R., Vigliocco G., Gramajo H., et al. Antenatal origin of neurologic damage in newborn infants. II. Multiple gestations. Am J Obstet Gynecol 162 (1990) 1230-1236
9. Adegbite A.L., Castille S., Ward S., and Bajoria R. Neuromorbidity in preterm twins in relation to chorionicity and discordant birth weight. Am J Obstet Gynecol 190 (2004) 156-163
10. Fries M.H., Goldstein R.B., Kilpatrick S.J., Golbus M.S., Callen P.W., and Filly R.A. The role of velamentous cord insertion in the etiology of twin-twin transfusion syndrome. Obstet Gynecol 81 (1993) 569-574
11. Machin G.A. Velamentous cord insertion in monochorionic twin gestation. An added risk factor. J Reprod Med 42 (1997) 785-789
12. Hanley M.L., Ananth C.V., Shen-Schwarz S., Smulian J.C., Lai Y.L., and Vintzileos A.M. Placental cord insertion and birth weight discordancy in twin gestations. Obstet Gynecol 99 (2002) 477-482
13. Fick A.L., Feldstein V.A., Norton M.E., Wassel F.C., Caughey A.B., and Machin G.A. Unequal placental sharing and birth weight discordance in monochorionic diamniotic twins. Am J Obstet Gynecol 195 (2006) 178-183
14. Patten R.M., Mack L.A., Harvey D., Cyr D.R., and Pretorius D.H. Disparity of amniotic fluid volume and fetal size: problem of the stuck twin-US studies. Radiology 172 (1989) 153-157
15. Bajoria R., Wigglesworth J., and Fisk N.M. Angioarchitecture of monochorionic placentas in relation to the twin-twin transfusion syndrome. Am J Obstet Gynecol 172 (1995) 856-863
16. Bajoria R. Vascular anatomy of monochorionic placenta in relation to discordant growth and amniotic fluid volume. Hum Reprod 13 (1998) 2933-2940
17. Denbow M.L., Cox P., Taylor M., Hammal D.M., and Fisk N.M. Placental angioarchitecture in monochorionic twin pregnancies: relationship to fetal growth, fetofetal transfusion syndrome, and pregnancy outcome. Am J Obstet Gynecol 182 (2000) 417-426
18. Wee L.Y., Taylor M., Watkins N., Franke V., Parker K., and Fisk N.M. Characterisation of deep arterio-venous anastomoses within monochorionic placentae by vascular casting. Placenta 26 (2005) 19-24
19. Sebire N.J., Talbert D., and Fisk N.M. Twin-to-twin transfusion syndrome results from dynamic asymmetrical reduction in placental anastomoses: a hypothesis. Placenta 22 (2001) 383-391
20. Lutfi S., Allen V.M., Fahey J., O'Connell C.M., and Vincer M.J. Twin-twin transfusion syndrome: a population-based study. Obstet Gynecol 104 (2004) 1289-1297
21. De Paepe M.E., DeKoninck P., and Friedman R.M. Vascular distribution patterns in monochorionic twin placentas. Placenta 26 (2005) 471-475
22. Denbow M., Fogliani R., Kyle P., Letsky E., Nicolini U., and Fisk N. Haematological indices at fetal blood sampling in monochorionic pregnancies complicated by feto-fetal transfusion syndrome. Prenat Diagn 18 (1998) 941-946
23. Mayhew T.M. Fetoplacental angiogenesis during gestation is biphasic, longitudinal and occurs by proliferation and remodelling of vascular endothelial cells. Placenta 23 (2002) 742-750
24. Charnock-Jones D.S., Kaufmann P., and Mayhew T.M. Aspects of human fetoplacental vasculogenesis and angiogenesis. I. Molecular regulation. Placenta 25 (2004) 103-113
25. Kaufmann P., Mayhew T.M., and Charnock-Jones D.S. Aspects of human fetoplacental vasculogenesis and angiogenesis. II. Changes during normal pregnancy. Placenta 25 (2004) 114-126
26. Lyall F., Greer I.A., Boswell F., and Fleming R. Suppression of serum vascular endothelial growth factor immunoreactivity in normal pregnancy and in pre-eclampsia. BJOG 104 (1997) 223-228
27. Kupferminc M.J., Daniel Y., Englender T., et al. Vascular endothelial growth factor is increased in patients with preeclampsia. Am J Reprod Immunol 38 (1997) 302-306
28. Torry D.S., Wang H.S., Wang T.H., Caudle M.R., and Torry R.J. Preeclampsia is associated with reduced serum levels of placenta growth factor. Am J Obstet Gynecol 179 (1998) 1539-1544
29. Tidwell S.C., Ho H.N., Chiu W.H., Torry R.J., and Torry D.S. Low maternal serum levels of placenta growth factor as an antecedent of clinical preeclampsia. Am J Obstet Gynecol 184 (2001) 1267-1272
30. Zhou Y., McMaster M., Woo K., et al. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am J Pathol 160 (2002) 1405-1423
31. Tsatsaris V., Goffin F., Munaut C., et al. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. J Clin Endocrinol Metab 88 (2003) 5555-5563
32. Maynard S.E., Min J.Y., Merchan J., et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 111 (2003) 649-658
33. Koga K., Osuga Y., Yoshino O., et al. Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. J Clin Endocrinol Metab 88 (2003) 2348-2351
34. McKeeman G.C., Ardill J.E., Caldwell C.M., Hunter A.J., and McClure N. Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop. Am J Obstet Gynecol 191 (2004) 1240-1246
35. Krauss T., Pauer H.U., and Augustin H.G. Prospective analysis of placenta growth factor (PlGF) concentrations in the plasma of women with normal pregnancy and pregnancies complicated by preeclampsia. Hypertens Pregnancy 23 (2004) 101-111
36. Levine R.J., Maynard S.E., Qian C., et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 350 (2004) 672-683
37. Chaiworapongsa T., Romero R., Espinoza J., et al. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. Am J Obstet Gynecol 190 (2004) 1541-1547
38. Thadhani R., Mutter W.P., Wolf M., et al. First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab 89 (2004) 770-775
39. Maynard S.E., Venkatesha S., Thadhani R., and Karumanchi S.A. Soluble Fms-like tyrosine kinase 1 and endothelial dysfunction in the pathogenesis of preeclampsia. Pediatr Res 57 (2005) 1R-7R
40. Chaiworapongsa T., Romero R., Kim Y.M., et al. Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med 17 (2005) 3-18
41. Redman C.W., and Sargent I.L. Latest advances in understanding preeclampsia. Science 308 (2005) 1592-1594
42. Bdolah Y., Karumanchi S.A., and Sachs B.P. Recent advances in understanding of preeclampsia. Croat Med J 46 (2005) 728-736
43. Levine R.J., Thadhani R., Qian C., et al. Urinary placental growth factor and risk of preeclampsia. JAMA 293 (2005) 77-85
44. Rajakumar A., Michael H.M., Rajakumar P.A., et al. Extra-placental expression of vascular endothelial growth factor receptor-1, (Flt-1) and soluble Flt-1 (sFlt-1), by peripheral blood mononuclear cells (PBMCs) in normotensive and preeclamptic pregnant women. Placenta 26 (2005) 563-573
45. Levine R.J., and Karumanchi S.A. Circulating angiogenic factors in preeclampsia. Clin Obstet Gynecol 48 (2005) 372-386
46. Shibata E., Rajakumar A., Powers R.W., et al. Soluble fms-like tyrosine kinase 1 is increased in preeclampsia but not in normotensive pregnancies with small-for-gestational-age neonates: relationship to circulating placental growth factor. J Clin Endocrinol Metab 90 (2005) 4895-4903
47. Staff A.C., Braekke K., Harsem N.K., Lyberg T., and Holthe M.R. Circulating concentrations of sFlt1 (soluble fms-like tyrosine kinase 1) in fetal and maternal serum during pre-eclampsia. Eur J Obstet Gynecol Reprod Biol 122 (2005) 33-39
48. Espinoza J., Nien J.K., Kusanovic J.P., et al. The combined use of uterine artery Doppler and maternal plasma placental growth factor concentrations identifies patients at risk for early onset and/or severe preeclampsia. Ultrasound Obstet Gynecol 28 (2006) 387-388
49. Venkatesha S., Toporsian M., Lam C., et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 12 (2006) 642-649
50. Robinson C.J., Johnson D.D., Chang E.Y., Armstrong D.M., and Wang W. Evaluation of placenta growth factor and soluble Fms-like tyrosine kinase 1 receptor levels in mild and severe preeclampsia. Am J Obstet Gynecol 195 (2006) 255-259
51. Aggarwal P.K., Jain V., Sakhuja V., Karumanchi S.A., and Jha V. Low urinary placental growth factor is a marker of pre-eclampsia. Kidney Int 69 (2006) 621-624
52. Levine R.J., Lam C., Qian C., et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 355 (2006) 992-1005
53. Levine R.J., Qian C., Maynard S.E., Yu K.F., Epstein F.H., and Karumanchi S.A. Serum sFlt1 concentration during preeclampsia and mid trimester blood pressure in healthy nulliparous women. Am J Obstet Gynecol 194 (2006) 1034-1041
54. Crispi F., Dominguez C., Llurba E., Martin-Gallan P., Cabero L., and Gratacos E. Placental angiogenic growth factors and uterine artery Doppler findings for characterization of different subsets in preeclampsia and in isolated intrauterine growth restriction. Am J Obstet Gynecol 195 (2006) 201-207
55. Malamitsi-Puchner A., Boutsikou T., Economou E., et al. Vascular endothelial growth factor and placenta growth factor in intrauterine growth-restricted fetuses and neonates. Mediators Inflamm 2005 (2005) 293-297
56. Boutsikou T., Malamitsi-Puchner A., Economou E., Boutsikou M., Puchner K.P., and Hassiakos D. Soluble vascular endothelial growth factor receptor-1 in intrauterine growth restricted fetuses and neonates. Early Hum Dev 82 (2006) 235-239
57. Girardi G., Yarilin D., Thurman J.M., Holers V.M., and Salmon J.E. Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J Exp Med 203 (2006) 2165-2175
58. Padavala S., Pope N., Baker P., and Crocker I. An imbalance between vascular endothelial growth factor and its soluble receptor in placental villous explants of intrauterine growth-restricted pregnancies. J Soc Gynecol Investig 13 (2006) 40-47
59. Wallner W., Sengenberger R., Strick R., et al. Angiogenic growth factors in maternal and fetal serum in pregnancies complicated by intrauterine growth restriction. Clin Sci (Lond) 112 (2007) 51-57
60. Signore C., Mills J.L., Qian C., et al. Circulating angiogenic factors and placental abruption. Obstet Gynecol 108 (2006) 338-344
61. Espinoza J., Nien J.K., Kusanovic J.P., et al. A role of the anti-angiogenic factor sVEGFR-1 in the 'mirror syndrome' (Ballantyne's syndrome). Am J Obstet Gynecol 193 (2005) S134
62. Espinoza J., Romero R., Nien J.K., et al. A role of the anti-angiogenic factor sVEGFR-1 in the 'mirror syndrome' (Ballantyne's syndrome). J Matern Fetal Neonatal Med 19 (2006) 607-613
63. Rana S., Venkatesha S., DePaepe M., Chien E.K., Paglia M., and Karumanchi S.A. Cytomegalovirus-induced mirror syndrome associated with elevated levels of circulating antiangiogenic factors. Obstet Gynecol 109 (2007) 549-552
64. Stepan H., and Faber R. Elevated sFlt1 level and preeclampsia with parvovirus-induced hydrops. N Engl J Med 354 (2006) 1857-1858
65. Espinoza J., Chaiworapongsa T., Romero R., et al. Unexplained fetal death: another anti-angiogenic state. J Matern Fetal Neonatal Med 20 (2007) 495-507
66. Kumazaki K., Nakayama M., Suehara N., and Wada Y. Expression of vascular endothelial growth factor, placental growth factor, and their receptors Flt-1 and KDR in human placenta under pathologic conditions. Hum Pathol 33 (2002) 1069-1077
67. Scardo J.A., Ellings J.M., and Newman R.B. Prospective determination of chorionicity, amnionicity, and zygosity in twin gestations. Am J Obstet Gynecol 173 (1995) 1376-1380
68. Sepulveda W., Sebire N.J., Hughes K., Odibo A., and Nicolaides K.H. The lambda sign at 10-14 weeks of gestation as a predictor of chorionicity in twin pregnancies. Ultrasound Obstet Gynecol 7 (1996) 421-423
69. Wood S.L., St O.R., Connors G., and Elliot P.D. Evaluation of the twin peak or lambda sign in determining chorionicity in multiple pregnancy. Obstet Gynecol 88 (1996) 6-9
70. Bracero L.A., and Byrne D.W. Ultrasound determination of chorionicity and perinatal outcome in twin pregnancies using dividing membrane thickness. Gynecol Obstet Invest 55 (2003) 50-57
71. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 183 (2000) S1-S22
72. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. No. 33, January 2002. Obstet Gynecol 99 (2002) 159-167
73. Sibai B.M., Ewell M., Levine R.J., et al. Risk factors associated with preeclampsia in healthy nulliparous women. The Calcium for Preeclampsia Prevention (CPEP) Study Group. Am J Obstet Gynecol 177 (1997) 1003-1010
74. Alexander G.R., Himes J.H., Kaufman R.B., Mor J., and Kogan M. A United States national reference for fetal growth. Obstet Gynecol 87 (1996) 163-168
75. Gonzalez R.P., Gomez R.M., Castro R.S., et al. [A national birth weight distribution curve according to gestational age in Chile from 1993 to 2000]. Rev Med Chil 132 (2004) 1155-1165
76. Quintero R.A., Morales W.J., Allen M.H., Bornick P.W., Johnson P.K., and Kruger M. Staging of twin-twin transfusion syndrome. J Perinatol 19 (1999) 550-555
77. Quintero R.A., Quintero L., Pivatelli A., Bornick P.W., Allen M., and Johnson P. The donor-recipient (D-R) score: in vivo endoscopic evidence to support the hypothesis of a net transfer of blood from donor to recipient in twin-twin transfusion syndrome. Prenat Neonat Med 5 (2000) 84-91
78. Bermudez C., Becerra C.H., Bornick P.W., Allen M.H., Arroyo J., and Quintero R.A. Placental types and twin-twin transfusion syndrome. Am J Obstet Gynecol 187 (2002) 489-494
79. Bermudez C., Becerra C., Bornick P.W., Allen M.H., Arroyo J., and Quintero R.A. Twin-twin transfusion syndrome with only superficial placental anastomoses: endoscopic and pathological evidence. J Matern Fetal Neonatal Med 12 (2002) 138-140
80. Lewi L., Van S.D., Gratacos E., Witters I., Timmerman D., and Deprest J. Monochorionic diamniotic twins: complications and management options. Curr Opin Obstet Gynecol 15 (2003) 177-194
81. Galea P., Jain V., and Fisk N.M. Insights into the pathophysiology of twin-twin transfusion syndrome. Prenat Diagn 25 (2005) 777-785
82. Harkness U.F., and Crombleholme T.M. Twin-twin transfusion syndrome: where do we go from here?. Semin Perinatol 29 (2005) 296-304
83. Bajoria R., Ward S., and Chatterjee R. Natriuretic peptides in the pathogenesis of cardiac dysfunction in the recipient fetus of twin-twin transfusion syndrome. Am J Obstet Gynecol 186 (2002) 121-127
84. Mahieu-Caputo D., Dommergues M., Delezoide A.L., et al. Twin-to-twin transfusion syndrome. Role of the fetal renin-angiotensin system. Am J Pathol 156 (2000) 629-636
85. Sooranna S.R., Ward S., and Bajoria R. Discordant fetal leptin levels in monochorionic twins with chronic midtrimester twin-twin transfusion syndrome. Placenta 22 (2001) 392-398
86. Bajoria R., Gibson M.J., Ward S., Sooranna S.R., Neilson J.P., and Westwood M. Placental regulation of insulin-like growth factor axis in monochorionic twins with chronic twin-twin transfusion syndrome. J Clin Endocrinol Metab 86 (2001) 3150-3156
87. Nevo O., Many A., Xu J., et al. Placental expression of sFlt-1 is increased in singletons and twin pregnancies with intrauterine growth restriction. J Clin Endocrinol Metab 93 (2008) 285-292
88. Heyborne K.D., and Chism D.M. Reversal of Ballantyne syndrome by selective second-trimester fetal termination. A case report. J Reprod Med 45 (2000) 360-362
89. Audibert F., Salomon L.J., Castaigne-Meary V., Alves K., and Frydman R. Selective termination of a twin pregnancy as a treatment of severe pre-eclampsia. BJOG 110 (2003) 68-69
90. Heyborne K.D., and Porreco R.P. Selective fetocide reverses preeclampsia in discordant twins. Am J Obstet Gynecol 191 (2004) 477-480
91. Pirhonen J.P., and Hartgill T.W. Spontaneous reversal of mirror syndrome in a twin pregnancy after a single fetal death. Eur J Obstet Gynecol Reprod Biol 116 (2004) 106-107
92. Audibert F., Saloman L.J., and Frydman R. Selective fetocide reverses preeclampsia in discordant twins. Am J Obstet Gynecol 193 (2005) 894-895
93. Romero R., Nien J.K., Espinoza J., et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic/soluble endoglin and soluble endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small-for-gestational-age neonate. J Matern Fetal Neonatal Medicine 21 (2008) 9-23